Supported by La Roche-Posay
This program will provide an overview of AD including prevalence, severity, and disease course/progression, succinct summaries of pathophysiology and medical management, and discussion of epidermal barrier dysfunction and skin microbiome shifting associated with AD. Additional emphasis is placed on adjunctive topical skin barrier approaches that may prolong disease-free remissions. Results from a panel of dermatologists queried about adjunctive approaches to AD, using a modified-Delphi approach, are also discussed.
James Q. Del Rosso, DO, FAOCD, FAAD
JDR Dermatology Research/Thomas Dermatology
Las Vegas, Nevada